NICE OKs More Sovaldi And Olysio Indications, Raising Payment Concerns
NICE has recommended additional indications for Janssen’s Olysio and Gilead’s Sovaldi for hepatitis C, but high costs could result in delayed payments from a cash-strapped NHS.
NICE has recommended additional indications for Janssen’s Olysio and Gilead’s Sovaldi for hepatitis C, but high costs could result in delayed payments from a cash-strapped NHS.